Global Schizophrenia Therapeutics Market 2014-2018
|出版商||TechNavio (Infiniti Research Ltd.)||商品編碼||319675|
|出版日期||內容資訊||英文 102 Pages
|全球思覺失調症治療藥市場 Global Schizophrenia Therapeutics Market 2014-2018|
|出版日期: 2014年11月19日||內容資訊: 英文 102 Pages||
Schizophrenia is a chronic brain disorder that severely affects the quality of life of a patient by disturbing the normal functioning of the brain. Psychotic symptoms and a diminished range of expression of emotions are the characteristics of schizophrenia. The exact etiology of schizophrenia is still not known. In men, it appears in the late teens or early 20s, and in women in the late 20s or early 30s. However, most of the symptoms of this disorder can be managed with medication and psychological help.
TechNavio's analysts forecast the Global Schizophrenia Therapeutics market to grow at a CAGR of 2.82 percent over the period 2013-2018.
This report covers the present scenario and the growth prospects of the Global Schizophrenia Therapeutics market for the period 2014-2018. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of schizophrenia that are available in the market. The Global Schizophrenia Therapeutics market can be segmented into two: First-generation Antipsychotics and Second-generation Antipsychotics.
TechNavio's report, the Global Schizophrenia Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Schizophrenia Therapeutics market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.